Burning Rock Biotech (BNR) FCF Margin (2019 - 2026)

Burning Rock Biotech (BNR) has reported FCF Margin for 8 consecutive years, with 27.03% the latest figure, recorded in Q1 2026.

• In Q1 2026, FCF Margin fell 939.0% year-over-year to 27.03%; the TTM figure through Mar 2026 stood at 11.01% (up 2713.0% YoY), while the FY2025 annual figure was 6.25%, up 1269.0% from the prior year.
• FCF Margin came in at 27.03% for Q1 2026 at Burning Rock Biotech, down from 18.23% in the prior quarter.
• The five-year high for FCF Margin was 18.23% in Q4 2025, with the low at 106.39% in Q1 2022.
• Average FCF Margin over 5 years is 43.06%, with a median of 45.25% recorded in 2025.
• Across the five-year window, FCF Margin plunged 4937 bps in 2024 and jumped 9893 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 46.16% in 2022, then surged by 71 bps to 13.23% in 2023, then jumped by 214 bps to 15.12% in 2024, then gained by 21 bps to 18.23% in 2025, then plunged by 248 bps to 27.03% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 27.03%, 18.23%, and 12.39% for Q1 2026, Q4 2025, and Q3 2025 respectively.